lymphocytes in cancer cell areas and in surrounding stroma). P3028 was graded (semi-quantitatively) as high or low. Quantitative flow cytometry was performed focusing on CD8+, CD3+, and CD4+ T-cells, macrophages and dendritic cells.

The study was approved by the Swedish Ethical Review Authority (no. 2017/580). Written informed consent was obtained from the patients. A copy of the written consent is available for review by the Editor of this journal.

Results Based on immunohistochemistry focusing on presence and distribution of CD8+ T-cells, most TC lesions were found to be of an 'inflamed' immune phenotype. This particular phenotype also featured low expression of immunosuppressive peptide P3028 (cf. other immune phenotypes). Flow cytometry verified that 'immune excluded' and 'inflamed' cancer lesions were associated with high levels of CD8+ T-cells (cf. desert lesions). The presence of CD3+ and CD4+ T-cells as well as macrophages and dendritic cells in relation to immune phenotypes were indicated.

Conclusions TC lesions may be classified into 'inflamed', 'immune excluded', and 'desert' phenotypes based on presence and distribution of CD8+ T-cells. Other immune cells may be associated with these immune phenotypes, including CD3+ and CD4+ T-cells, macrophages, and dendritic cells. P3028 is present in TC lesions: low levels of this immunosuppressive peptide are observed in the 'inflamed' phenotype. Arguably, P3028 prevents successful recruitment of immune cells in TC. Inferentially, presence and distribution of P3028 may be considered as a prognostic marker as well as a treatment target of this condition.

Ethics Approval The study was approved by the Swedish Ethical Review Authority (no. 2017/580).

Consent Written informed consent was obtained from the patients. A copy of the written consent is available for review by the Editor of this journal.

<http://dx.doi.org/10.1136/jitc-2020-SITC2020.0840>

Immune-stimulants and immune modulators

841 CRISPR CAS9 LIBRARY SCREEN IN PRIMARY T CELLS AND DIFFUSE LARGE B CELL LYMPHOMA CELLS TO IDENTIFY MODULATORS IN TUMOR-IMMUNE INTERACTION

Qian Li, Zhengang Peng*. *WXI ApTec (Shanghai) Co., Ltd., Shanghai, China*

Background Immunotherapy, especially checkpoint blockers targeting programmed cell death protein 1 (PD-1) pathways, has transformed cancer treatment. Current checkpoint blockers are limited by low response rate, side effect and treatment relapse. The emergence of CRISPR Cas9-based screen provides a superior and powerful tool in gene function profiling. The application of CRISPR Cas9 screen in primary immune cells and tumor cells such as diffuse large B cell lymphoma (DLBCL) cells will accelerate the identification of key regulators in tumor-immune interaction.

Methods CRISPR screen using membrane protein-focused sgRNA library and genome-scale sgRNA library; primary T cell and tumor cell co-culture

Results First of all, we developed a CRISPR-Cas9 gene targeting method that can achieve efficient gene disruption in primary CD8+T cells isolated from mouse (~60% efficiency) or human (~70% efficiency). We have applied this method to a pooled

CRISPR library screen for key modulators of T cell-induced cytotoxicity against cancer cells in vitro. This customized library contains sgRNAs targeting nearly all membrane proteins expressed in both murine and human T cells. For our in vitro screen, mouse colorectal cancer cell line MC38 expressing chicken ovalbumin (Ova) were co-cultured with Ova-specific CD8+T cells isolated from OT-I transgenic mice. The proliferation and function of CD8+ T cell were dampened by tumor cells in an antigen-dependent way. On the other hand, we successfully developed a genome-scale CRISPR screen platform on the difficult-to-transduce DLBCL cells. The platform is currently deployed to validate modulators involved in bispecific antibody-mediated tumor cell killing by T cells.

Conclusions We have established CRISPR Cas9 pooled screen platforms for identification of modulators of tumor-immune interaction by either target primary T cells or difficult-to-transduce DLBCL cells.

<http://dx.doi.org/10.1136/jitc-2020-SITC2020.0841>

842 A NOVEL AGONISTIC ANTI-CD40 TARGETING STRATEGY WITH AN AFFINITY PEPTIDE BINDING FEATURE FOR ANTIGEN CARGO FUNCTIONALITY: IMPROVING PEPTIDE STABILITY AND T CELL PROLIFERATION

Ida Olsson*, Mohamed Eltahir, Sara Mangsbo. *Uppsala University, Uppsala, Sweden*

Background To induce a prominent anti-tumor T-cell response, a viral or tumor derived antigen epitope imbedded in a longer synthetic peptide (SLP) can be used, which also requires internalization and processing by antigen presenting cells (APCs) to enable T cell priming. Herein we present the design and evaluation of a CD40 targeting tetravalent bispecific antibody, binding peptides through affinity as an antibody-drug conjugate. APC activation as well as in vitro and in vivo T-cell proliferation studies demonstrate retained agonistic activity as well as improved T cell proliferation/expansion in vitro and in vivo, compared to non-linked peptide/antibody mixes.

Methods T-cell priming was evaluated with B3Z assay or a cytomegalovirus (CMV) model and displayed superior uptake to non-bound peptide in the co-stimulatory independent B3Z assay. In addition, intracellular peptide release in APCs was analysed using a unique quenching strategy displaying peptide release after around 4-6 hour post antigen.

Results Peptide stability in vitro, when bound to the antibody, was analysed by mass spectrometry and displayed prolonged peptide stability in serum, increasing the peptide half-life by 15 times in vitro (

Conclusions Data support that the novel delivery system can improve antigen targeting to dendritic cells, but can also provide a prolonged peptide half-life as well as a peptide delivery to APCs. Combined this improves the efficiency of both antigen delivery and CD40 agonistic functionality.

<http://dx.doi.org/10.1136/jitc-2020-SITC2020.0842>

843 REPRODUCIBLE, MOA-REFLECTING REPORTER-BASED BIOASSAYS TO ENABLE DRUG DEVELOPMENT OF BIOSIMILARS AND BIOBETTERS

Jeffrey Nelson*, Richard Moravec, Dun Li, Jennifer Wilkinson, Frank Fan, Mei Cong. *Promega, Madison, USA*

Background Cytokines and growth factors are small immunomodulatory proteins secreted by a wide variety of cells (e.g.

fibroblasts, endothelial and stromal cells) that regulate surrounding cells via autocrine, paracrine or endocrine mechanisms. Immunocytokines are a promising class of activators of the immune system, with the potential to be used alone or in combination with other therapeutic agents to treat a variety of disease including autoimmunity and cancer. This class of biologics includes FDA-approved cytokine therapies (e.g. IFN, IL-2 and Epo) as well as an increasing number of biologics designed to block cytokine activity. The latter class of biologics includes basiliximab (IL-2R), tocilizumab and sarilumab (IL-6R), siltuximab (IL-6), ustekinumab and its biosimilars (IL-12/IL-23 p40), secukinumab (IL-17A), bevasizumab (VEGF), and denosumab (RANKL). Pharmaceutical pipelines include an increasing number of biosimilar and biobetter molecules with sustained and targeted activities with a goal to improve drug potency, patient tolerance and clinical response.

Methods Quantitative and reproducible functional bioassays are critical for the development and manufacture of biologics drugs targeting cytokine and growth factor pathways. In many cases, existing bioassays rely on the use of primary cells and measurement of complex endpoints. These assays are highly variable, difficult to implement, and often fail to yield data quality required for drug development in a quality-controlled environment. To address this problem, we have developed a suite of bioluminescent luciferase-based reporter bioassays that can be used to quantitatively measure the activity of specific cytokines and growth factors, including: IL-2, IL-6, IL-12, IL-15, IL-17, IL-23, VEGF and RANKL.

Results These mechanism of action (MOA) reflecting bioassays exhibit the required performance metrics for use in potency and stability studies. Importantly, these bioassays have been optimized in a thaw-and-use cell format, which eliminates the need for cell culture and ensures high reproducibility, convenience and transferability.

Conclusions In summary, bioluminescent reporter-based bioassays offer significant advantages over primary cell-based bioassays and are valuable tools for the development and manufacturing of novel biologics targeting cytokine and growth factor pathways.

<http://dx.doi.org/10.1136/jitc-2020-SITC2020.0843>

844

IMMUNOMODULATORY ACTIVITY OF EPIGENETIC DRUGS COMBINATIONS IN MESOTHELIOMA: LAYING THE GROUND FOR NEW IMMUNOTHERAPEUTIC STRATEGIES

Sara Cannito, Health Biology*, Ornella Cutaia, Carolina Fazio, Maria Fortunata Lofiego, Francesca Piazzini, Laura Solmonese, Luana Calabrò, Michele Maio, Alessia Covre. *Center for Immuno-Oncology, Siena, Italy*

Background Growing evidence are demonstrating the therapeutic efficacy of immune checkpoint inhibitors (ICI) in mesothelioma; however, a limited percentage of patients benefits from this therapeutic approach. Epigenetic modifications play a relevant role in negatively regulating the cross-talk between neoplastic and immune cells, and in contributing to the highly immunosuppressive mesothelioma microenvironment. A better understanding of mesothelioma epigenetic landscape could open the path to novel and potentially more effective approaches combining ICI and epigenetic drugs. We investigated the immunomodulatory potential of epigenetic agents by

comparing the activity of DNA hypomethylating agents (DHA) with histone deacetylases inhibitors (HDACi) and EZH2 inhibitors (EZH2i), alone or combined with DHA, in mesothelioma cells.

Methods Four mesothelioma cell lines were treated with the DHA guadecitabine 1μM, or with the HDACi, Valproic Acid (VPA) 1mM, or the EZH2i, EPZ-6438 1μM, alone or combined with guadecitabine. We investigated the expression of HLA class I molecules by flow-cytometry and of PD-L1, cancer testis antigens (CTA: NY-ESO, MAGE-A1), Natural Killer Group 2 member D Ligands (NKG2DLs: MIC-A, MIC-B, ULBP2) and EMT-regulating cadherins (CDH1, CDH2) by quantitative Real-Time PCR. Fold change (FC) expression for each treatment vs untreated cells was reported as mean values (FCm) among investigated cell lines. A positive modulation of the expression was considered if FCm>1.5.

Results Guadecitabine upregulated the expression of HLA class I antigens (FCm=1.75), PD-L1 (FCm=2.38), NKG2DLs (MIC-A FCm=1.96, MIC-B FCm=2.57, and ULBP2 FCm=3.56), and upregulated/induced CTA expression. Similarly, VPA upregulated HLA class I antigens (FCm=1.67), PD-L1 (FCm=3.17), NKG2DLs (MIC-A FCm=1.78, MIC-B FCm=3.04, and ULBP2 FCm=3.75) expression; however, CTA expression was modulated only in 1 mesothelioma cell line. Conversely, EPZ-6438 up-regulated only NY-ESO-1 and MIC-B expression in 1 mesothelioma cell line.

The addition of both VPA and EPZ-6483 to guadecitabine strengthened its immunomodulatory activity. Specifically, guadecitabine plus VPA or EPZ-6438 upregulated the expression of HLA class I antigens FCm=2.55 or 2.69, PD-L1 FCm=8.04 or 2.65, MIC-A FCm=3.81 or 2.26, MIC-B FCm=8.00 or 3.03, ULBP2 FCm=6.24 or 4.53, respectively. Higher levels of CTA upregulation/induction were observed with combination treatments vs guadecitabine alone.

Cadherins modulation was mesothelioma histotype-related: CDH1 expression was induced in the 2 constitutively-negative sarcomatoid mesothelioma cells by guadecitabine alone or combined with VPA or EPZ-6438; CDH2 expression was upregulated by VPA alone (FCm=1.53) or plus guadecitabine (FCm=2.54).

Conclusions Combination of DHA-based immunotherapies with other classes of epigenetic drugs could be an effective strategy to be pursued in the mesothelioma clinic.

<http://dx.doi.org/10.1136/jitc-2020-SITC2020.0844>

845

DEVELOPING MORE POTENT INHIBITORS OF VASOACTIVE INTESTINAL PEPTIDE SIGNALING WITH ENHANCED EFFICACY IN MOUSE MODELS OF LEUKEMIA

¹Sruthi Ravindranathan*, ¹Jian-ming Li, ¹Yiwen Li, ¹Passang Tenzin, ²Anish Majumdar, ¹Edmund Waller. *¹Emory University, Tucker, GA, USA; ²Cambium Oncology, Menlo Park, CA, USA*

Background Vasoactive intestinal peptide (VIP) is an immunosuppressive neuropeptide that significantly affect proliferation and anti-tumor properties of T cells.¹⁻³ VIP overexpression is a potential mechanism of immune escape in solid tumors with paracrine VIP production. Our published work shows that inhibiting VIP receptor (VIP-R) signaling via VIPhyb, an antagonistic fusion peptide between neurotensin and VIP, improves T cell dependent anti-tumor response in mouse models of acute myeloid leukemia (AML) and T lymphoblastic leukemia